• White blood cell disorders

Rolvedon Generic Name & Formulations

General Description

Eflapegrastim-xnst 13.2mg/0.6mL; soln for SC inj; preservative-free.

Pharmacological Class

Granulocyte colony stimulating factor.

How Supplied

Single-dose prefilled syringe—1 (w. supplies)

Generic Availability


Rolvedon Indications


To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia.

Limitations of Use

Not for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Rolvedon Dosage and Administration


Give 13.2mg by SC inj once per chemotherapy cycle. Administer ~24 hours after cytotoxic chemotherapy. Do not give within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.


Not established.

Rolvedon Contraindications


History of serious allergic reactions, including anaphylaxis, to eflapegrastim, pegfilgrastim, or filgrastim products.

Rolvedon Boxed Warnings

Not Applicable

Rolvedon Warnings/Precautions


Monitor for enlarged spleen or splenic rupture, and for acute respiratory distress syndrome (ARDS); evaluate if symptoms occur; discontinue if ARDS is diagnosed. Permanently discontinue if serious allergic reactions occur. Sickle cell disorders; discontinue if sickle cell crisis occurs. Evaluate if glomerulonephritis is suspected; consider dose reduction or interruption if treatment-related. Monitor CBCs, platelets during therapy; discontinue if WBC count ≥100x109/L occurs. Monitor closely if symptoms of capillary leak syndrome develop. Discontinue if aortitis is suspected. Tumor growth factor (eg, myeloid malignancies, myelodysplasia). Monitor for MDS/AML in those with breast or lung cancer. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.

Rolvedon Pharmacokinetics

See Literature

Rolvedon Interactions

Rolvedon Adverse Reactions

Adverse Reactions

Fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, back pain; ARDS, splenic rupture, glomerulonephritis, leukocytosis, capillary leak syndrome, thrombocytopenia.

Rolvedon Clinical Trials

See Literature

Rolvedon Note

Not Applicable

Rolvedon Patient Counseling

See Literature